There were 2,242 press releases posted in the last 24 hours and 359,201 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Menlo Therapeutics Announces Completion of Enrollment in Two Phase 3 Trials of Serlopitant in Prurigo Nodularis

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image